entertainment -WSS

entertainment

author：explore 2025-10-02 00:53:08 - browse：955

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Illumina board agrees to spin off Grail, as divestment plans proceed

leisure time

WSS

Illumina to lay off 10% of research and development team

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

FTC loses bid to block Novant's North Carolina hospital merger

The simple reason for the increase in autism diagnosis

The most pressing bird flu mysteries scientists want answered

Why do we get seasonal allergies?

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Hepatitis C has a cure — but many Americans still lack access to it

A new initiative will help leaders fight the next pandemic

Wildfire smoke exposes gaps in outdoor worker protections

How CO2 helps viruses stay alive longer in the air

Moonlake's readout produced a cash windfall. Risks remain

Ukrainian soldiers say they owe lives to US

Anesthesiologist group: stop taking Ozempic before surgery

Eating disorder hotline's move to chatbot carried cost for volunteers

hotspot

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Finland to offer bird flu vaccine to select groups of people, a possible global first

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

A new initiative will help leaders fight the next pandemic

How CO2 helps viruses stay alive longer in the air

Supreme Court strikes down Biden student loan forgiveness program

leisure time

leisure time

hotspot

entertainment